Skip to content
+91-79-4107-8000
info@lincolnpharma.com
Facebook page opens in new window
X page opens in new window
Instagram page opens in new window
Linkedin page opens in new window
YouTube page opens in new window
Lincoln Pharmaceuticals
Healthcare for All
Home
About Us
Operations
Domestic
Operations
Products
Divisions
International
Operations
Products
Contact
Portfolio
Key Brands
Products
New Launches
Manufacturing
Capabilities
Certifications
Quality Control & Assurance
EHS Policy
Business Opportunity
R & D
Highlights
Infrastructure
Innovation
Collaboration
Acts of Science
Activities
Investors
Careers
Contact
Home
About Us
Operations
Domestic
Operations
Products
Divisions
International
Operations
Products
Contact
Portfolio
Key Brands
Products
New Launches
Manufacturing
Capabilities
Certifications
Quality Control & Assurance
EHS Policy
Business Opportunity
R & D
Highlights
Infrastructure
Innovation
Collaboration
Acts of Science
Activities
Investors
Careers
Contact
Outcome of Board Meetings
You are here:
Home
Investors
Disclosures under Regulation 46 of the LODR
Outcome of Board Meetings
2024-2025
Q1
2023-2024
Q1
Q2
Q3
Q4
Appointment of ID, Reconstitution of Committee & Postal Ballot
2022-2023
Q1
Q2
Q3
Q4
Reconstitution of Committees
2021-2022
Q1
Q2
Q3
Q4
Allotment of Shares
2020-2021
Q1
Q2
Q3
Q4
2019-2020
Q1
Q2
Q3
Q4
Approved Interim Dividend of Rs. 1.50 Per Share
Consider and Approve Scheme of Merger
Intimation of scheme of Amalgamation
2018-2019
Q1
Q2
Q3
Q4
Appointment of CFO
2017-2018
Q1
Q2
Q3
Q4
Appointment of Director
Go to Top